BOLT Bolt Biotherapeutics, Inc.

Bolt Biotherapeutics, Inc., a clinical-stage immuno-oncology company, engages in the discovery, development, and commercialization of pharmaceutical products. The company develops BDC-1001, a human epidermal growth factor receptor 2 (HER2) for the treatment of patients with HER2-expressing solid tumors, including HER2-low tumors. Its preclinical stage product candidates include carcinoembryonic antigen program for colorectal, non-small cell lung, pancreatic, and breast cancers; programmed cell death-ligand 1 program for tumors that are nonresponsive to immune checkpoint blockade; and myeloid modulators. Bolt Biotherapeutics, Inc. was founded in 2015 and is based Redwood city, California.

$10.55  +0.16 (1.54%)
As of 12/03/2021 15:59:56 EST     IEX book   CBOE book

Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Small cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  02/05/2021
Outstanding shares:  37,284,650
Average volume:  309,603
Market cap:   $387,387,514
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    097702104
ISIN:        US0977021049
Sedol:      BMDJ397
Valuation   (See tab for details)
PE ratio:   -4.96
PB ratio:   1.42
PS ratio:   319.10
Return on equity:   -37.27%
Net income %:   -8,440.61%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy